SBI-0646535

SBI-0646535 is a small molecule positive allosteric modulator (PAM) of the Group II metabotropic glutamate receptors, specifically mGlu2 and mGlu3. Developed by the Sanford Burnham Prebys Medical Discovery Institute, it is being investigated as a novel therapeutic for schizophrenia, with a focus on addressing cognitive dysfunction and symptoms that are exacerbated by estrogen deficiency (e.g., during menopause). Preclinical research indicates that SBI-0646535 can reverse N-methyl-D-aspartate receptor (NMDAR) hypofunction-related deficits, such as elevations in cortical gamma power and attentional impairments induced by the NMDAR antagonist MK-801. Its mechanism of action involves enhancing glutamatergic neurotransmission through mGlu2/3 receptors, providing a potential alternative or adjunct to traditional antipsychotics that may be less effective in hormone-deprived states.